Enhanced antitumor effect of binimetinib in combination with capecitabine for biliary tract cancer patients with mutations in the RAS/RAF/MEK/ERK pathway: phase Ib study

BACKGROUND: A phase Ib study of binimetinib and capecitabine for gemcitabine-pretreated biliary tract cancer (BTC) patients was conducted. METHODS: Binimetinib and capecitabine were dosed twice daily on days 1–14, in 3-week cycles. In the dose-escalation (DE) part, three dose levels (DL) were tested...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin Won, Lee, Kyung-Hun, Kim, Ji-Won, Suh, Koung Jin, Nam, Ah-Rong, Bang, Ju-Hee, Bang, Yung-Jue, Oh, Do-Youn
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738070/
https://www.ncbi.nlm.nih.gov/pubmed/31312030
http://dx.doi.org/10.1038/s41416-019-0523-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738070/
https://www.ncbi.nlm.nih.gov/pubmed/31312030
http://dx.doi.org/10.1038/s41416-019-0523-5

Ejemplares similares